This report is designed for companies and decision-makers seeking actionable insights on market size, growth, trends, and competitive strategies to drive expansion and success in the Enjaymo industry.
What is the current market size of the enjaymo industry, and what growth rate is it expected to achieve?
The enjaymo market size has XX (HCAGR) in recent years. It will grow from $XX million in 2024 to $XX million in 2025 at a compound annual growth rate (CAGR) of XX%. The growth in the historic period can be attributed to increased appeal of Iptacopan, demand for cold agglutinin disease drugs, increased lactate dehydrogenase values (LDH) in the blood, demand for disease-specific treatment, and increased awareness.
The enjaymo market size is expected to see XX (FCAGR) in the next few years. It will grow to $XX million in 2029 at a compound annual growth rate (CAGR) of XX%. The growth in the forecast period can be attributed to increasing research and development activities, rising prevalence of cold agglutinin disease, growing awareness about the disease, rising patient population, and increasing R&D activities. Major trends in the forecast period include innovative treatment options, advancements in diagnostic technologies, an increase in the number of research and development activities, advanced technologies, and advancements in diagnostic technologies.
Download Your Free Sample PDF:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20058&type=smp
What are the major drivers contributing to the growth of the enjaymo market?
The increasing prevalence of autoimmune disorders is expected to propel the growth of the enjaymo market going forward. Autoimmune disorders refer to a group of diseases where the immune system, which normally defends the body against harmful invaders such as bacteria and viruses, mistakenly attacks the body’s own healthy tissues and organs. The rising prevalence of autoimmune disorders is attributed to improved diagnostics, environmental changes, dietary shifts, sedentary lifestyles, and factors like chronic stress and the hygiene hypothesis affecting immune system regulation. Enjaymo, a monoclonal antibody therapy, helps patients with autoimmune disorders by targeting and inhibiting the complement system, specifically C1s, thereby preventing the activation of the immune response that contributes to the destruction of red blood cells, offering significant relief from hemolytic anemia associated with conditions like cold agglutinin disease and other autoimmune hemolytic disorders. For instance, in June 2024, according to a report published by the Australian Institute of Health and Welfare, an Australian-based governmental organization, in 2021–22, there were 10,000 hospitalizations for rheumatoid arthritis, a 25% increase from the previous year’s 8,000, equating to a rate of 39 hospitalizations per 100,000 population. Therefore, increasing prevalence of autoimmune disorders is driving the growth of the enjaymo market.
What are the major market segments driving the growth of the enjaymo industry?
The enjaymo market covered in this report is segmented –
1) By Clinical Indication: Cold Agglutinin Disease (CAD), Autoimmune Hemolytic Anemia (AIHA), Complement-Mediated Hemolytic Disorders, Off-Label Uses (Emerging Indications)
2) By Drug Class: Monoclonal Antibodies, Corticosteroids, Immunosuppressants, Other Biological Therapies
3) By Distribution Channels: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
View The Full Market Report:
https://www.thebusinessresearchcompany.com/report/enjaymo-global-market-report
What are the key trends shaping the enjaymo market in the forecast period?
Key trend in the enjaymo market include obtaining regulatory approvals for drugs to enhance treatment accessibility and ensure compliance with global healthcare standards. Regulatory approvals refer to the official authorization granted by governmental or regulatory bodies, such as the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA), allowing a drug to be marketed and sold. For instance, in January 2023, Sanofi S.A., a France-based pharmaceutical industry company, received FDA approval for Enjaymo (sutimlimab-jome), allowing its use in adults with cold agglutinin disease (CAD) regardless of transfusion history. Enjaymo works by targeting the classical complement pathway, preventing the immune system from attacking red blood cells. The updated formulation also offers a more convenient administration method, reducing infusion time to one hour biweekly. This approval represents a significant advancement in treatment options for CAD patients, enhancing their quality of life.
Who are the key market players contributing to the growth of the enjaymo industry?
Major companies operating in the enjaymo market include Recordati Industria Chimica e Farmaceutica S.p.A.
Which regions are leading the growth of the enjaymo market globally?
North America was the largest region in the enjaymo market in 2024. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the enjaymo market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
How Can Companies Use The Enjaymo Market Report to Drive Business Results?
This report provides actionable insights tailored for business use—not academic analysis. Companies can leverage the data to:
• Time market entry or expansion using growth forecasts and CAGR trends.
• Develop competitive products by tracking key technology shifts and user preferences.
• Tailor regional strategies with in-depth geographic data and local market dynamics.
• Benchmark and plan partnerships using competitive landscape insights.
Purchase The Report And Get A Swift Delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20058
Need Customized Data On Enjaymo Market?
For companies needing more tailored intelligence, The Business Research Company offers customized consulting and data services. Whether you’re entering new regions, launching innovative products, or assessing M&A opportunities, our experts can develop actionable insights specific to your business objectives.
Request Customized Data:
https://www.thebusinessresearchcompany.com/customise?id=20058&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
https://thebusinessresearchcompany.com/
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
